Hence, serglycin proteoglycans contribute to the control of the enteropathy, possibly through mechanisms mediated via its negatively charged glycosaminoglycan chains, i.e. as a co-factor of inflammatory mediators. Here, SRGN is linked to Abnormal intestine morphology.